On November 4, 2021 Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, reported it will present preclinical data on the characterization of WU-CART-007 at the 63rd Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) which will be held virtually and in-person in Atlanta, Georgia from December 11-14, 2021 (Press release, Wugen, NOV 4, 2021, View Source [SID1234594542]). The results demonstrate preclinical safety and anti-tumor activity of WU-CART-007. Wugen is preparing to begin enrollment for a Phase 1/2 clinical trial for relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (LBL) (NCT#04984356).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The details of Wugen’s presentation at ASH (Free ASH Whitepaper) are as follows:
Title: Characterization of WU-CART-007, an Allogeneic CD7-Targeted CAR-T Cell Therapy for T-Cell Malignancies
Abstract Number: 2772
Poster session: Session 703. Cellular Immunotherapies: Basic and Translational
Date and time: Sunday, December 12, 2021, 6:00 – 8:00 p.m. ET
Location: Hall B5 (Georgia World Congress Center)
Authors: Tom Leedom, Alexander S. Hamil, Ph.D., Somayeh Pouyanfard, Jennifer Govero, Ph.D., Rachel Langland, B.Sc., Anna Ballard, Ph.D., Liz Schwarzkopf, Andrew Martens, Andrew Espenschied, Pooja Vinay, M.S., Michael James, Nitin Mahajan, Ph.D., David H. Spencer, M.D., Kenneth M. Chrobak, Ph.D., Matthew L Cooper, Ph.D., and Ayman Kabakibi, Ph.D.